Andrew M. Scharenberg, M.D.
Dr. Andrew M. Scharenberg is an Entrepreneur at MPM BioImpact. Andrew is the founder and CEO of portfolio company Umoja Biopharma. Prior to founding Umoja, Andrew was an Attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine in Seattle.
While at Seattle Children’s/UW, Andrew co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, partnered with Casebia Therapeutics for the purpose of developing a gene edited cell therapeutic for Type I diabetes and other inflammatory diseases. Previously, he was the Chief Scientific Officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform, and co-founder of Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. He also serves on the scientific advisory boards of Alpine Immune Sciences (chair), Generation Bio (chair), Genti Bio (chair), and Tessera Therapeutics.
Andrew earned his M.D. from the University of North Carolina School of Medicine, and then completed residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital. Andrew received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is an active member of the American Society for Clinical Investigation and the American Pediatric Society.